Article Text
Drug therapy
Editorial
Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases
Statistics from Altmetric.com
Footnotes
-
Funding The Swedish Medical Products Agency, The IMI project BT-CURE (Grant agreement No. 115142-1) and the Biobanking and Molecular Resource Infrastructure of Sweden (BBMRI.se).
-
Competing interests None.
-
Provenance and peer review Not commissioned; externally peer reviewed.
-
Data sharing statement Data of this study are open for access.